Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Mouse study shows how liraglutide briefly rewires gut bacterial communities

4

Aug 2026

Mouse study shows how liraglutide briefly rewires gut bacterial communities

Researchers treated male high-fat-fed mice with liraglutide for 14 days, then tracked fecal bacterial communities after a 7-day washout using 16S rRNA sequencing. Liraglutide shifted the microbiome toward Lactobacillus- and Leptogranulimonas-related taxa while reducing several fermentative taxa, but most changes moved back toward baseline after treatment stopped.

Occupational pesticide exposure may significantly increase ALS risk

4

Aug 2026

Occupational pesticide exposure may significantly increase ALS risk

Workplace exposure to pesticides (herbicides and insecticides) is linked to a 60-70% heightened risk of the most common form of motor neuron disease-amyotrophic lateral sclerosis, or ALS for short, finds a synthesis of the available evidence, published online in Occupational & Environmental Medicine.

Study maps how birth order tracks disease risk across 10 million siblings

4

Aug 2026

Study maps how birth order tracks disease risk across 10 million siblings

Researchers analyzing claims from more than 10 million siblings linked first-born status to higher odds of several neurodevelopmental and allergic diagnoses, while second-born status tracked with substance abuse and gastrointestinal conditions. The observational study identified 150 significant birth-order associations across the phenome, but claims data and residual confounding prevent causal conclusions.

NIH funds smartphone platform to improve driving safety for teens

4

Aug 2026

NIH funds smartphone platform to improve driving safety for teens

Dr. Jeffrey Keller, Hibernia National Bank/Edward G. Schleider Endowed Chair at LSU's Pennington Biomedical Research Center, and Sara Seifert, president of Minnesota HealthSolutions, have received a new National Institutes of Health Small Business Innovation Research (SBIR) award to develop an innovative digital health platform that will help parents support teenagers with attention-deficit/hyperactivity disorder (ADHD) as they learn to drive.

Complex ophthalmology letters may hinder patient understanding, study suggests

4

Aug 2026

Complex ophthalmology letters may hinder patient understanding, study suggests

Letters to patients from ophthalmology services--the highest volume outpatient specialty in UK healthcare-include too much complex language and medical terminology which patients are likely to find hard to understand, reveals an analysis of more than 4 million letters from one large hospital trust, published in the open access journal BMJ Health & Care Informatics.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.